midazolam Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1802 59467-70-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • buccolam
  • midazolam
  • mezolam
  • midazolam hydrochloride
  • midazolam HCl
A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
  • Molecular weight: 325.77
  • Formula: C18H13ClFN3
  • CLOGP: 3.42
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 30.18
  • ALOGS: -4.52
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg N
15 mg O
15 mg P
10 mg SL

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 10.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 5.60 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.26 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 44 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 5.30 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 3.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 1985 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 471.39 13.75 208 27464 13771 46644619
Hypotension 246.32 13.75 470 27202 232119 46426271
Anaphylactic reaction 239.86 13.75 220 27452 52892 46605498
Cardiac arrest 230.90 13.75 276 27396 90123 46568267
Serotonin syndrome 221.38 13.75 152 27520 24068 46634322
Propofol infusion syndrome 179.95 13.75 49 27623 732 46657658
Drug interaction 163.59 13.75 367 27305 202727 46455663
Seizure 157.03 13.75 270 27402 122784 46535606
Fatigue 154.30 13.75 85 27587 608612 46049778
Anaphylactic shock 152.44 13.75 113 27559 20161 46638229
Generalised tonic-clonic seizure 145.61 13.75 124 27548 26998 46631392
Respiratory acidosis 140.60 13.75 70 27602 6078 46652312
Tachycardia 139.59 13.75 228 27444 99394 46558996
Multiple organ dysfunction syndrome 137.02 13.75 161 27511 51549 46606841
Multiple-drug resistance 126.22 13.75 50 27622 2515 46655875
Delayed recovery from anaesthesia 122.03 13.75 37 27635 824 46657566
Bradycardia 121.55 13.75 172 27500 66126 46592264
Anaesthetic complication 120.35 13.75 44 27628 1773 46656617
Labile blood pressure 104.55 13.75 39 27633 1664 46656726
Agitation 103.39 13.75 145 27527 55270 46603120
Drug ineffective 102.47 13.75 718 26954 677120 45981270
Circulatory collapse 102.26 13.75 92 27580 21532 46636858
Diabetes insipidus 102.18 13.75 41 27631 2133 46656257
Diarrhoea 95.73 13.75 115 27557 559487 46098903
Unwanted awareness during anaesthesia 94.23 13.75 24 27648 272 46658118
Unresponsive to stimuli 93.32 13.75 105 27567 32069 46626321
Delirium 87.31 13.75 109 27563 37119 46621271
Nausea 86.41 13.75 174 27498 687280 45971110
Fall 85.96 13.75 44 27628 329053 46329337
Respiratory depression 85.71 13.75 64 27608 11536 46646854
Drug ineffective for unapproved indication 83.93 13.75 73 27599 16340 46642050
Pulseless electrical activity 82.54 13.75 52 27620 7115 46651275
Metabolic acidosis 82.22 13.75 108 27564 38672 46619718
Headache 82.05 13.75 98 27574 478254 46180136
Myoclonus 81.92 13.75 68 27604 14284 46644106
Renal ischaemia 81.56 13.75 25 27647 578 46657812
Shock 78.72 13.75 80 27592 21765 46636625
Mitochondrial DNULL mutation 78.18 13.75 20 27652 231 46658159
Respiratory failure 76.84 13.75 172 27500 94644 46563746
Joint swelling 75.81 13.75 6 27666 166067 46492323
Neuromuscular block prolonged 75.40 13.75 23 27649 523 46657867
Encephalopathy 75.04 13.75 96 27576 33493 46624897
Partial seizures 74.93 13.75 43 27629 4967 46653423
Arthralgia 73.43 13.75 65 27607 364538 46293852
Oxygen saturation decreased 73.12 13.75 140 27532 69024 46589366
Intestinal ischaemia 71.73 13.75 47 27625 6878 46651512
Apnoea 71.63 13.75 48 27624 7291 46651099
Alopecia 68.51 13.75 8 27664 162406 46495984
Pain in extremity 68.37 13.75 34 27638 258646 46399744
Cardiogenic shock 68.34 13.75 65 27607 16319 46642071
Anticholinergic syndrome 67.76 13.75 29 27643 1777 46656613
Procedural complication 67.61 13.75 40 27632 4890 46653500
Anaesthetic complication neurological 67.54 13.75 17 27655 183 46658207
Bronchospasm 66.82 13.75 63 27609 15644 46642746
Blood pH decreased 66.31 13.75 32 27640 2595 46655795
Intra-abdominal pressure increased 65.93 13.75 17 27655 203 46658187
Disseminated intravascular coagulation 63.78 13.75 67 27605 18938 46639452
Electroencephalogram abnormal 63.69 13.75 35 27637 3719 46654671
PCO2 increased 63.64 13.75 25 27647 1229 46657161
Malaise 63.19 13.75 62 27610 331170 46327220
Pneumatosis 63.18 13.75 19 27653 411 46657979
Oxygen saturation abnormal 62.30 13.75 31 27641 2687 46655703
PO2 increased 60.61 13.75 22 27650 868 46657522
Abdominal discomfort 60.03 13.75 9 27663 151156 46507234
Stress cardiomyopathy 59.87 13.75 44 27628 7740 46650650
Hypoxia 59.86 13.75 109 27563 51729 46606661
Methaemoglobinaemia 59.65 13.75 28 27644 2134 46656256
Procedural hypotension 57.64 13.75 23 27649 1179 46657211
Renal impairment 56.99 13.75 132 27540 74240 46584150
Pain 56.14 13.75 125 27547 476823 46181567
Acute respiratory distress syndrome 54.31 13.75 66 27606 21856 46636534
Mydriasis 54.07 13.75 47 27625 10506 46647884
Electrocardiogram QRS complex prolonged 54.05 13.75 36 27636 5413 46652977
Electrocardiogram ST segment elevation 53.36 13.75 31 27641 3664 46654726
Product dose omission issue 52.91 13.75 17 27655 168503 46489887
Sinus tachycardia 51.72 13.75 64 27608 21585 46636805
Ventricular hypokinesia 50.53 13.75 31 27641 4047 46654343
Ventricular tachycardia 50.25 13.75 56 27616 16911 46641479
Peripheral swelling 49.52 13.75 16 27656 158055 46500335
Foetal death 49.01 13.75 41 27631 8702 46649688
Ventricular extrasystoles 48.26 13.75 45 27627 11018 46647372
Electrocardiogram ST segment depression 48.16 13.75 26 27646 2667 46655723
Drug intolerance 47.66 13.75 14 27658 147035 46511355
Depressed level of consciousness 47.46 13.75 94 27578 47475 46610915
Dizziness 47.11 13.75 81 27591 340333 46318057
Necrosis ischaemic 46.98 13.75 18 27654 827 46657563
Gene mutation 46.07 13.75 19 27653 1061 46657329
Blood lactic acid increased 45.83 13.75 33 27639 5624 46652766
Anaesthetic complication pulmonary 45.79 13.75 10 27662 54 46658336
Weight decreased 45.58 13.75 35 27637 210814 46447576
Epilepsy 45.56 13.75 63 27609 23675 46634715
Systemic inflammatory response syndrome 45.05 13.75 32 27640 5339 46653051
Blood gases abnormal 44.30 13.75 16 27656 622 46657768
Nasopharyngitis 44.15 13.75 18 27654 153980 46504410
Kounis syndrome 44.11 13.75 19 27653 1183 46657207
Epileptic aura 43.94 13.75 10 27662 67 46658323
Renal injury 43.93 13.75 40 27632 9501 46648889
Fear 43.87 13.75 51 27621 16121 46642269
Blood bicarbonate decreased 43.78 13.75 25 27647 2860 46655530
Upper airway obstruction 43.03 13.75 15 27657 525 46657865
Hyperaesthesia 42.30 13.75 36 27636 7820 46650570
Hepatic failure 42.08 13.75 73 27599 33343 46625047
Perforation 40.87 13.75 17 27655 970 46657420
Hypoventilation 40.39 13.75 27 27645 4083 46654307
Hepatic ischaemia 40.11 13.75 14 27658 492 46657898
Non-consummation 39.08 13.75 9 27663 64 46658326
Anorectal ulcer 39.08 13.75 9 27663 64 46658326
Haemodynamic instability 38.76 13.75 34 27638 7691 46650699
Cardiotoxicity 38.67 13.75 32 27640 6690 46651700
Pseudopolyp 37.16 13.75 11 27661 225 46658165
Blood pressure decreased 36.90 13.75 95 27577 57064 46601326
Blood creatine phosphokinase increased 36.80 13.75 62 27610 27662 46630728
Post procedural complication 36.77 13.75 46 27626 15683 46642707
Swelling 36.59 13.75 14 27658 124497 46533893
Arthropathy 36.12 13.75 4 27668 84696 46573694
Psoriasis 35.40 13.75 3 27669 78601 46579789
Restlessness 35.11 13.75 58 27614 25466 46632924
Unmasking of previously unidentified disease 35.09 13.75 14 27658 717 46657673
Brain oedema 34.93 13.75 40 27632 12438 46645952
Altered state of consciousness 34.76 13.75 55 27617 23293 46635097
Airway peak pressure increased 34.70 13.75 11 27661 285 46658105
Sinusitis 34.32 13.75 17 27655 129751 46528639
Hepatorenal syndrome 33.86 13.75 18 27654 1790 46656600
Hypernatraemia 33.79 13.75 29 27643 6372 46652018
Airway complication of anaesthesia 33.67 13.75 10 27662 207 46658183
Coma 33.64 13.75 93 27579 58256 46600134
Clonus 33.51 13.75 24 27648 4056 46654334
Diabetic macroangiopathy 33.14 13.75 9 27663 133 46658257
Septic shock 33.11 13.75 92 27580 57801 46600589
Back pain 32.81 13.75 46 27626 209993 46448397
Myalgia 32.74 13.75 16 27656 123072 46535318
Laryngeal stenosis 32.38 13.75 13 27659 677 46657713
Weight increased 32.21 13.75 30 27642 164443 46493947
Sinus bradycardia 31.73 13.75 40 27632 13742 46644648
Hepatocellular injury 31.47 13.75 60 27612 29462 46628928
Asthenia 31.46 13.75 88 27584 310987 46347403
Muscle rigidity 31.44 13.75 34 27638 9927 46648463
Oliguria 31.40 13.75 32 27640 8727 46649663
Bronchitis 31.00 13.75 12 27660 105967 46552423
Toxicity to various agents 30.85 13.75 223 27449 211543 46446847
Left ventricular dysfunction 30.63 13.75 34 27638 10221 46648169
Infusion related reaction 30.37 13.75 11 27661 101197 46557193
Systolic dysfunction 30.15 13.75 15 27657 1299 46657091
Product administered to patient of inappropriate age 29.64 13.75 19 27653 2677 46655713
Encephalitis autoimmune 29.30 13.75 14 27658 1110 46657280
Muscle relaxant therapy 29.28 13.75 8 27664 121 46658269
Therapeutic product effect prolonged 29.16 13.75 10 27662 333 46658057
Gastrointestinal scarring 29.16 13.75 9 27663 213 46658177
Asthma 29.13 13.75 9 27663 91533 46566857
Ventricular fibrillation 29.10 13.75 35 27637 11461 46646929
Off label use 28.96 13.75 348 27324 379493 46278897
Contusion 28.94 13.75 8 27664 87479 46570911
Renal failure 28.46 13.75 138 27534 113456 46544934
Tachyphylaxis 28.18 13.75 9 27663 239 46658151
Palpitations 27.51 13.75 11 27661 95248 46563142
Ultrasound ovary abnormal 27.43 13.75 7 27665 80 46658310
Acid base balance abnormal 27.43 13.75 9 27663 261 46658129
Pruritus 27.22 13.75 65 27607 242287 46416103
Anhedonia 27.04 13.75 32 27640 10303 46648087
Cardiac arrest neonatal 27.04 13.75 7 27665 85 46658305
Hyperammonaemic encephalopathy 26.96 13.75 16 27656 1966 46656424
Pupils unequal 26.93 13.75 14 27658 1330 46657060
Urinary tract infection 26.42 13.75 57 27615 220209 46438181
Rhabdomyolysis 26.37 13.75 69 27603 41840 46616550
Influenza 26.29 13.75 10 27662 89260 46569130
Sedation 26.21 13.75 48 27624 22862 46635528
Laryngospasm 26.15 13.75 18 27654 2855 46655535
Musculoskeletal stiffness 25.66 13.75 13 27659 97980 46560410
Patent ductus arteriosus 25.65 13.75 20 27652 3842 46654548
Abdominal pain upper 25.62 13.75 29 27643 145276 46513114
Systemic lupus erythematosus 25.58 13.75 4 27668 65176 46593214
Acidosis hyperchloraemic 25.39 13.75 9 27663 331 46658059
Tryptase increased 25.32 13.75 8 27664 205 46658185
Hypoaesthesia 25.32 13.75 20 27652 118849 46539541
Pituitary apoplexy 25.25 13.75 7 27665 112 46658278
Atrioventricular dissociation 24.89 13.75 8 27664 217 46658173
Wrong product administered 24.74 13.75 23 27649 5607 46652783
Arrhythmia 24.67 13.75 60 27612 34781 46623609
Bulimia nervosa 24.65 13.75 10 27662 535 46657855
Gait disturbance 24.53 13.75 30 27642 145233 46513157
Anuria 24.47 13.75 32 27640 11399 46646991
Respiratory rate increased 24.46 13.75 32 27640 11401 46646989
Post procedural stroke 24.33 13.75 6 27666 59 46658331
Paradoxical drug reaction 24.30 13.75 16 27656 2360 46656030
Neurotoxicity 24.23 13.75 35 27637 13682 46644708
Injection site pain 24.15 13.75 17 27655 107135 46551255
Hypotonia 24.09 13.75 27 27645 8202 46650188
Carcinoid crisis 24.06 13.75 8 27664 242 46658148
Exposure during pregnancy 23.97 13.75 127 27545 108085 46550305
Incorrect route of product administration 23.57 13.75 38 27634 16345 46642045
Myoglobin blood increased 23.29 13.75 13 27659 1423 46656967
Drug reaction with eosinophilia and systemic symptoms 23.22 13.75 53 27619 29495 46628895
Syncope 23.13 13.75 17 27655 104786 46553604
Gastrointestinal mucosa hyperaemia 22.67 13.75 7 27665 166 46658224
Cough 22.62 13.75 66 27606 230183 46428207
Acute hepatic failure 22.36 13.75 35 27637 14686 46643704
Muscle spasms 22.33 13.75 24 27648 123089 46535301
Neonatal seizure 22.25 13.75 8 27664 307 46658083
Infection parasitic 22.25 13.75 8 27664 307 46658083
Overdose 22.12 13.75 119 27553 101860 46556530
Drug tolerance 22.10 13.75 17 27655 3201 46655189
Electrocardiogram repolarisation abnormality 22.03 13.75 12 27660 1253 46657137
Procedural vomiting 21.90 13.75 9 27663 498 46657892
Contraindicated product administered 21.85 13.75 10 27662 79937 46578453
Ventricular dysfunction 21.76 13.75 16 27656 2816 46655574
Constipation 21.75 13.75 44 27628 174053 46484337
Coronary artery embolism 21.60 13.75 7 27665 195 46658195
Dyspnoea 21.43 13.75 199 27473 515349 46143041
White blood cell count decreased 21.35 13.75 21 27651 112210 46546180
Pulse absent 21.31 13.75 20 27652 4936 46653454
Hyperthermia 21.28 13.75 25 27647 7989 46650401
Intensive care unit delirium 21.20 13.75 5 27667 40 46658350
Pneumothorax 21.14 13.75 34 27638 14595 46643795
Eosinophilic pneumonia acute 21.10 13.75 8 27664 357 46658033
Acute coronary syndrome 20.97 13.75 28 27644 10176 46648214
Rash 20.82 13.75 125 27547 356387 46302003
Tonsillar hypertrophy 20.68 13.75 10 27662 814 46657576
Pulmonary oedema 20.66 13.75 72 27600 51033 46607357
Loss of consciousness 20.63 13.75 122 27550 108116 46550274
Electrocardiogram QT prolonged 20.48 13.75 72 27600 51253 46607137
Musculoskeletal pain 20.40 13.75 8 27664 70120 46588270
Hyperammonaemia 20.21 13.75 19 27653 4697 46653693
Intensive care unit acquired weakness 19.87 13.75 9 27663 632 46657758
Dyschezia 19.63 13.75 12 27660 1556 46656834
Oedema peripheral 19.41 13.75 41 27631 159665 46498725
Drug resistance 19.38 13.75 36 27636 17332 46641058
Dehydration 19.35 13.75 41 27631 159499 46498891
Blood magnesium decreased 19.35 13.75 28 27644 10964 46647426
Chest pain 19.22 13.75 48 27624 176276 46482114
C-reactive protein decreased 19.17 13.75 9 27663 686 46657704
Hypertonia 19.16 13.75 18 27654 4448 46653942
Colitis 19.07 13.75 57 27615 37290 46621100
Delayed graft function 19.07 13.75 10 27662 967 46657423
Apnoeic attack 19.03 13.75 7 27665 287 46658103
Nephrocalcinosis 18.97 13.75 10 27662 977 46657413
Euthyroid sick syndrome 18.86 13.75 5 27667 67 46658323
Anaphylactoid shock 18.78 13.75 7 27665 298 46658092
Cholestasis 18.71 13.75 46 27626 26847 46631543
Sinus arrest 18.54 13.75 12 27660 1719 46656671
Hyperthermia malignant 18.53 13.75 9 27663 740 46657650
Neuromuscular blockade 18.37 13.75 7 27665 317 46658073
Acute respiratory failure 18.35 13.75 48 27624 29090 46629300
Drug-induced liver injury 18.30 13.75 44 27628 25324 46633066
Dry mouth 18.20 13.75 5 27667 54921 46603469
Opisthotonus 18.10 13.75 7 27665 330 46658060
Paralysis 18.02 13.75 24 27648 8697 46649693
Decreased appetite 18.00 13.75 57 27615 193779 46464611
Gastrooesophageal reflux disease 17.82 13.75 11 27661 74333 46584057
Herpes zoster 17.77 13.75 9 27663 67863 46590527
Granulomatous liver disease 17.69 13.75 9 27663 817 46657573
Respiratory arrest 17.64 13.75 52 27620 33764 46624626
White matter lesion 17.62 13.75 10 27662 1131 46657259
Immunosuppressant drug level increased 17.59 13.75 15 27657 3267 46655123
Acidosis 17.57 13.75 27 27645 11147 46647243
Left ventricular hypertrophy 17.55 13.75 18 27654 4945 46653445
Symptom masked 17.52 13.75 8 27664 572 46657818
Agitation postoperative 17.43 13.75 4 27668 28 46658362
Gastrointestinal vascular malformation 17.43 13.75 4 27668 28 46658362
Breast cancer 17.40 13.75 3 27669 45515 46612875
Torsade de pointes 17.22 13.75 28 27644 12126 46646264
Product contamination microbial 16.87 13.75 6 27666 223 46658167
Cardiac output decreased 16.85 13.75 9 27663 903 46657487
Abdominal rigidity 16.77 13.75 11 27661 1611 46656779
Foetal exposure during pregnancy 16.73 13.75 48 27624 30699 46627691
Jaundice acholuric 16.68 13.75 5 27667 107 46658283
Maternal exposure during pregnancy 16.68 13.75 111 27561 102438 46555952
Cardio-respiratory arrest 16.64 13.75 75 27597 59794 46598596
Rash morbilliform 16.63 13.75 14 27658 2995 46655395
Hypertrophic cardiomyopathy 16.52 13.75 10 27662 1274 46657116
Injection site erythema 16.51 13.75 12 27660 74415 46583975
Cardiac failure congestive 16.50 13.75 18 27654 91732 46566658
Gaze palsy 16.42 13.75 10 27662 1288 46657102
Posterior reversible encephalopathy syndrome 16.41 13.75 31 27641 15110 46643280
Stevens-Johnson syndrome 16.36 13.75 40 27632 23257 46635133
Tachypnoea 16.33 13.75 30 27642 14321 46644069
Neuroleptic malignant syndrome 16.28 13.75 26 27646 11096 46647294
Leukocytosis 16.25 13.75 40 27632 23358 46635032
Myocardial ischaemia 16.24 13.75 28 27644 12721 46645669
Epileptic encephalopathy 16.19 13.75 6 27666 251 46658139
Large intestinal ulcer 16.12 13.75 14 27658 3125 46655265
Product use in unapproved indication 16.08 13.75 100 27572 90173 46568217
Bone pain 16.05 13.75 4 27668 46886 46611504
Selective eating disorder 16.04 13.75 11 27661 1734 46656656
Cellulitis 16.03 13.75 11 27661 70277 46588113
Sleep disorder 16.00 13.75 4 27668 46791 46611599
Mobility decreased 15.92 13.75 8 27664 60586 46597804
Ileus paralytic 15.87 13.75 16 27656 4307 46654083
Female genital tract fistula 15.74 13.75 14 27658 3225 46655165
Respiratory distress 15.63 13.75 48 27624 31868 46626522
Device related sepsis 15.56 13.75 14 27658 3273 46655117
Haemodialysis 15.53 13.75 23 27649 9194 46649196
Supraventricular tachycardia 15.43 13.75 28 27644 13242 46645148
Hypochloraemia 15.34 13.75 11 27661 1862 46656528
Infantile apnoea 15.31 13.75 8 27664 768 46657622
Feeling abnormal 15.28 13.75 32 27640 125028 46533362
Stomatitis 15.17 13.75 11 27661 68286 46590104
Resuscitation 15.14 13.75 9 27663 1110 46657280
Foetal growth restriction 15.02 13.75 19 27653 6548 46651842
Hyperreflexia 14.97 13.75 17 27655 5237 46653153
Enzyme induction 14.93 13.75 4 27668 56 46658334
Tracheal injury 14.93 13.75 4 27668 56 46658334
Oxygen saturation immeasurable 14.90 13.75 3 27669 10 46658380
Chest discomfort 14.86 13.75 19 27653 90250 46568140
Weaning failure 14.83 13.75 6 27666 319 46658071
Drug level abnormal 14.80 13.75 4 27668 58 46658332
Manipulation 14.80 13.75 4 27668 58 46658332
Drug chemical incompatibility 14.80 13.75 4 27668 58 46658332
Burning sensation 14.80 13.75 4 27668 44407 46613983
Migraine 14.63 13.75 12 27660 70014 46588376
Rhinorrhoea 14.60 13.75 5 27667 47660 46610730
Pseudomonas infection 14.54 13.75 23 27649 9735 46648655
Influenza like illness 14.53 13.75 8 27664 57562 46600828
Blood cholesterol increased 14.52 13.75 3 27669 40010 46618380
Teratoma 14.48 13.75 5 27667 170 46658220
Conjunctival oedema 14.38 13.75 7 27665 578 46657812
Loss of personal independence in daily activities 14.36 13.75 8 27664 57175 46601215
Hot flush 14.35 13.75 4 27668 43513 46614877
Atrioventricular block first degree 14.31 13.75 18 27654 6168 46652222
Blood creatine phosphokinase MB increased 14.14 13.75 9 27663 1252 46657138
Acute kidney injury 14.13 13.75 207 27465 235648 46422742
Febrile infection-related epilepsy syndrome 14.10 13.75 3 27669 14 46658376
Blood methaemoglobin present 14.10 13.75 4 27668 70 46658320
Coma hepatic 14.04 13.75 7 27665 609 46657781
Spontaneous haemorrhage 14.03 13.75 5 27667 187 46658203
Catatonia 13.95 13.75 14 27658 3748 46654642
Local anaesthetic systemic toxicity 13.95 13.75 6 27666 372 46658018
Ammonia increased 13.92 13.75 15 27657 4362 46654028
Vocal cord dysfunction 13.85 13.75 5 27667 194 46658196
Acute generalised exanthematous pustulosis 13.78 13.75 22 27650 9383 46649007

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Status epilepticus 301.11 12.73 164 27613 10908 29913793
Anaphylactic reaction 224.75 12.73 195 27582 27787 29896914
Hypotension 221.68 12.73 538 27239 200027 29724674
Serotonin syndrome 194.97 12.73 149 27628 17742 29906959
Hyperthermia malignant 155.56 12.73 60 27717 1774 29922927
Propofol infusion syndrome 153.29 12.73 49 27728 817 29923884
Fatigue 136.06 12.73 64 27713 320609 29604092
Cardiac arrest 135.78 12.73 279 27498 92571 29832130
Bradycardia 122.98 12.73 219 27558 65307 29859394
Sedation 119.22 12.73 108 27669 16265 29908436
Seizure 110.26 12.73 266 27511 98209 29826492
Metabolic acidosis 108.82 12.73 153 27624 37308 29887393
Anaphylactic shock 107.22 12.73 95 27682 13898 29910803
Multiple organ dysfunction syndrome 102.59 12.73 199 27578 63288 29861413
Respiratory depression 102.18 12.73 85 27692 11418 29913283
Tachycardia 94.36 12.73 210 27567 73529 29851172
Delirium 91.01 12.73 147 27630 40484 29884217
Drug ineffective 89.17 12.73 579 27198 339808 29584893
Diarrhoea 87.70 12.73 109 27668 333994 29590707
Anaesthetic complication 87.20 12.73 34 27743 1035 29923666
Dizziness 87.04 12.73 36 27741 194873 29729828
Agitation 86.73 12.73 169 27608 53904 29870797
Rhabdomyolysis 81.24 12.73 181 27596 63399 29861302
Respiratory failure 78.50 12.73 238 27539 100404 29824297
Coma 76.86 12.73 136 27641 40313 29884388
Intensive care unit acquired weakness 72.07 12.73 28 27749 844 29923857
Delayed recovery from anaesthesia 70.21 12.73 26 27751 685 29924016
Brain oedema 69.82 12.73 71 27706 12327 29912374
Post procedural complication 67.58 12.73 68 27709 11658 29913043
Acute respiratory distress syndrome 66.84 12.73 95 27682 23377 29901324
Haemodynamic instability 66.59 12.73 57 27720 7958 29916743
Hypoxia 66.54 12.73 141 27636 47713 29876988
Product dose omission issue 65.93 12.73 5 27772 91626 29833075
Oxygen saturation decreased 65.10 12.73 132 27645 43308 29881393
Apnoea 63.52 12.73 50 27727 6208 29918493
Arthralgia 62.33 12.73 24 27753 135767 29788934
Procedural complication 61.53 12.73 43 27734 4454 29920247
Generalised tonic-clonic seizure 61.47 12.73 83 27694 19468 29905233
Fear 60.97 12.73 62 27715 10763 29913938
Fall 60.60 12.73 48 27729 181824 29742877
Diabetes insipidus 60.37 12.73 33 27744 2206 29922495
Drug ineffective for unapproved indication 58.90 12.73 61 27716 10819 29913882
Acidosis hyperchloraemic 57.94 12.73 18 27759 272 29924429
Drug reaction with eosinophilia and systemic symptoms 55.67 12.73 97 27680 28391 29896310
Autonomic nervous system imbalance 55.28 12.73 32 27745 2389 29922312
Headache 54.83 12.73 53 27724 182253 29742448
Unresponsive to stimuli 54.31 12.73 92 27685 26327 29898374
Drug interaction 54.15 12.73 343 27434 199225 29725476
Asthenia 53.04 12.73 77 27700 221213 29703488
Necrosis ischaemic 52.76 12.73 16 27761 222 29924479
Pain in extremity 51.37 12.73 19 27758 110202 29814499
Anaesthetic complication neurological 51.35 12.73 17 27760 318 29924383
Respiratory acidosis 50.20 12.73 37 27740 4165 29920536
Myalgia 47.95 12.73 7 27770 76660 29848041
Intestinal ischaemia 47.28 12.73 44 27733 6853 29917848
Seizure like phenomena 46.66 12.73 18 27759 532 29924169
Ventricular fibrillation 45.67 12.73 63 27714 15075 29909626
Dyspnoea 45.48 12.73 158 27619 333137 29591564
Peripheral swelling 44.88 12.73 3 27774 61071 29863630
Shock 44.87 12.73 78 27699 22781 29901920
Multiple-drug resistance 44.68 12.73 30 27747 2911 29921790
Nausea 43.79 12.73 136 27641 296821 29627880
Long QT syndrome 43.33 12.73 27 27750 2306 29922395
Toxic epidermal necrolysis 43.02 12.73 67 27710 17873 29906828
Septic shock 42.75 12.73 143 27634 63464 29861237
Catatonia 42.32 12.73 34 27743 4346 29920355
Blood pressure decreased 42.10 12.73 117 27660 46958 29877743
Brain death 41.55 12.73 27 27750 2479 29922222
Pulseless electrical activity 41.50 12.73 39 27738 6148 29918553
Ventricular tachycardia 41.20 12.73 77 27700 23785 29900916
Death 40.10 12.73 183 27594 357100 29567601
Malaise 40.05 12.73 58 27719 166904 29757797
Product administered to patient of inappropriate age 38.77 12.73 26 27751 2517 29922184
Mucosal ulceration 38.55 12.73 18 27759 860 29923841
Neuromuscular block prolonged 38.31 12.73 14 27763 355 29924346
Kounis syndrome 37.90 12.73 22 27755 1651 29923050
Neuroleptic malignant syndrome 37.88 12.73 60 27717 16235 29908466
Electrocardiogram ST segment elevation 37.73 12.73 32 27745 4410 29920291
Depressed level of consciousness 37.18 12.73 98 27679 38124 29886577
Circulatory collapse 37.13 12.73 67 27710 20147 29904554
Sedation complication 36.31 12.73 17 27760 817 29923884
Superinfection 35.97 12.73 21 27756 1593 29923108
Dehydration 35.86 12.73 37 27740 123502 29801199
Blood lactic acid increased 35.79 12.73 35 27742 5795 29918906
Hypercapnia 35.50 12.73 29 27748 3795 29920906
Decreased appetite 35.05 12.73 53 27724 149857 29774844
Electrocardiogram QT prolonged 34.98 12.73 92 27685 35743 29888958
Hypoventilation 34.72 12.73 26 27751 2997 29921704
Cyanosis 33.52 12.73 48 27729 11887 29912814
Unwanted awareness during anaesthesia 33.41 12.73 8 27769 41 29924660
Hypertransaminasaemia 33.03 12.73 28 27749 3857 29920844
Renal injury 32.69 12.73 47 27730 11682 29913019
Neonatal respiratory depression 32.61 12.73 13 27764 420 29924281
Respiratory arrest 32.61 12.73 79 27698 29179 29895522
Areflexia 32.61 12.73 24 27753 2695 29922006
Joint swelling 32.54 12.73 3 27774 46943 29877758
Emotional distress 32.52 12.73 55 27722 15710 29908991
Injury 32.49 12.73 66 27711 21665 29903036
Dyskinesia 32.27 12.73 66 27711 21768 29902933
Hyperthermia 31.93 12.73 43 27734 10056 29914645
Abdominal discomfort 31.58 12.73 4 27773 48787 29875914
Corneal reflex decreased 31.49 12.73 10 27767 163 29924538
Nasopharyngitis 31.25 12.73 8 27769 58841 29865860
COVID-19 pneumonia 31.19 12.73 29 27748 4511 29920190
Weight decreased 30.99 12.73 58 27719 150863 29773838
Artery dissection 30.72 12.73 9 27768 110 29924591
Trigemino-cardiac reflex 30.65 12.73 9 27768 111 29924590
Anticonvulsant drug level below therapeutic 30.60 12.73 14 27763 638 29924063
Intracranial pressure increased 29.35 12.73 25 27752 3465 29921236
Hyperexplexia 29.06 12.73 7 27770 37 29924664
Laryngospasm 28.68 12.73 17 27760 1326 29923375
Toxicity to various agents 28.61 12.73 270 27507 176913 29747788
Muscle rigidity 28.42 12.73 41 27736 10220 29914481
Acidosis 28.30 12.73 41 27736 10260 29914441
Myoclonus 28.20 12.73 47 27730 13265 29911436
Disseminated intravascular coagulation 28.14 12.73 63 27714 22108 29902593
Myocardial infarction 27.85 12.73 46 27731 125579 29799122
Anaesthetic complication pulmonary 27.60 12.73 6 27771 18 29924683
Pruritus 27.41 12.73 42 27735 118162 29806539
Back pain 27.27 12.73 33 27744 102563 29822138
Hyperammonaemia 26.43 12.73 29 27748 5491 29919210
Renal failure 26.29 12.73 207 27570 128759 29795942
White blood cell count decreased 25.66 12.73 24 27753 83923 29840778
Respiratory distress 24.73 12.73 77 27700 32895 29891806
Arteriospasm coronary 24.61 12.73 20 27757 2598 29922103
Tachypnoea 24.26 12.73 47 27730 14905 29909796
Cardio-respiratory arrest 23.96 12.73 111 27666 57195 29867506
Pupil fixed 23.86 12.73 17 27760 1815 29922886
Drug withdrawal syndrome 23.71 12.73 55 27722 19754 29904947
Oedema peripheral 23.22 12.73 39 27738 105793 29818908
Hepatitis fulminant 22.97 12.73 23 27754 3918 29920783
Hypocapnia 22.96 12.73 7 27770 99 29924602
Anhedonia 22.54 12.73 33 27744 8336 29916365
Plasma cell myeloma 22.04 12.73 11 27766 53451 29871250
Epilepsy 21.98 12.73 54 27723 20115 29904586
Coagulopathy 21.76 12.73 51 27726 18436 29906265
Shoshin beriberi 21.76 12.73 6 27771 58 29924643
Hospitalisation 21.73 12.73 7 27770 44312 29880389
Stress cardiomyopathy 21.63 12.73 15 27762 1534 29923167
Hyperammonaemic encephalopathy 21.49 12.73 16 27761 1828 29922873
Dystonia 21.49 12.73 35 27742 9692 29915009
Off label use 21.39 12.73 337 27440 248953 29675748
Chronic obstructive pulmonary disease 21.39 12.73 8 27769 46118 29878583
Tryptase increased 21.35 12.73 8 27769 218 29924483
Haemophagocytic lymphohistiocytosis 21.32 12.73 35 27742 9756 29914945
Anaemia 21.23 12.73 110 27667 207882 29716819
Nystagmus 21.13 12.73 23 27754 4315 29920386
Hyperaesthesia 21.10 12.73 21 27756 3552 29921149
Mydriasis 20.72 12.73 27 27750 6116 29918585
Cardiac failure congestive 20.53 12.73 29 27748 84378 29840323
Neuromuscular blockade 20.30 12.73 7 27770 149 29924552
Parkinsonism 20.06 12.73 29 27748 7240 29917461
Weight increased 20 12.73 24 27753 74889 29849812
Appendicitis perforated 19.92 12.73 15 27762 1743 29922958
Disease progression 19.86 12.73 27 27750 79847 29844854
Illusion 19.82 12.73 11 27766 757 29923944
Therapeutic product effect prolonged 19.52 12.73 8 27769 278 29924423
Neuropathy peripheral 19.44 12.73 22 27755 70453 29854248
Procedural hypotension 19.38 12.73 12 27765 1013 29923688
Drug resistance 18.94 12.73 51 27726 20082 29904619
Hypoglycaemia 18.85 12.73 12 27765 50969 29873732
Periorbital swelling 18.74 12.73 7 27770 189 29924512
Encephalopathy 18.67 12.73 69 27708 32136 29892565
Postresuscitation encephalopathy 18.66 12.73 4 27773 11 29924690
Overdose 18.64 12.73 138 27639 84199 29840502
Mumps 18.44 12.73 6 27771 106 29924595
Pseudomonal sepsis 18.40 12.73 18 27759 2982 29921719
Cardiogenic shock 18.22 12.73 45 27732 16816 29907885
Electrocardiogram QRS complex prolonged 17.97 12.73 21 27756 4256 29920445
Heart alternation 17.95 12.73 3 27774 0 29924701
Chest pain 17.88 12.73 53 27724 117574 29807127
Nerve block 17.72 12.73 4 27773 15 29924686
Pneumomediastinum 17.51 12.73 14 27763 1777 29922924
Staring 17.50 12.73 13 27764 1480 29923221
Conversion disorder 17.43 12.73 8 27769 367 29924334
Bronchospasm 17.39 12.73 33 27744 10305 29914396
Aggression 17.31 12.73 74 27703 36833 29887868
Asthma 17.23 12.73 6 27771 36168 29888533
Paraesthesia 17.23 12.73 15 27762 54312 29870389
Victim of homicide 17.22 12.73 6 27771 132 29924569
Methaemoglobinaemia 17.17 12.73 16 27761 2494 29922207
Suspiciousness 17.15 12.73 8 27769 381 29924320
Respiratory disorder 17.15 12.73 45 27732 17449 29907252
Upper airway obstruction 17.01 12.73 9 27768 563 29924138
Opisthotonus 16.98 12.73 8 27769 390 29924311
Pulse absent 16.84 12.73 23 27754 5450 29919251
Musculoskeletal pain 16.82 12.73 4 27773 30936 29893765
Abdominal pain upper 16.74 12.73 20 27757 62531 29862170
Cerebral ventricle dilatation 16.73 12.73 10 27767 792 29923909
Tonic clonic movements 16.61 12.73 11 27766 1043 29923658
Blood creatine phosphokinase MB increased 16.43 12.73 14 27763 1942 29922759
Dyspepsia 16.34 12.73 4 27773 30325 29894376
Arthrofibrosis 16.19 12.73 5 27772 74 29924627
Periventricular haemorrhage neonatal 16.18 12.73 4 27773 24 29924677
Ventricular extrasystoles 16.15 12.73 34 27743 11440 29913261
Haematuria traumatic 16.03 12.73 6 27771 163 29924538
Product contamination 15.95 12.73 9 27768 640 29924061
Intensive care 15.95 12.73 7 27770 289 29924412
Abdominal compartment syndrome 15.87 12.73 10 27767 871 29923830
Fear of death 15.83 12.73 9 27768 649 29924052
Drug withdrawal syndrome neonatal 15.75 12.73 17 27760 3158 29921543
Constipation 15.67 12.73 53 27724 112853 29811848
Post procedural haemorrhage 15.53 12.73 27 27750 7883 29916818
Clonus 15.43 12.73 15 27762 2466 29922235
Distractibility 15.32 12.73 7 27770 318 29924383
Automatism 15.23 12.73 5 27772 91 29924610
Acute pulmonary oedema 15.21 12.73 26 27751 7489 29917212
Catheter site haemorrhage 15.16 12.73 14 27763 2158 29922543
Administration related reaction 15.13 12.73 5 27772 93 29924608
Sinusitis 15.10 12.73 6 27771 33339 29891362
Partial seizures 15.01 12.73 18 27759 3749 29920952
Completed suicide 15.00 12.73 45 27732 99447 29825254
Neutropenia 14.84 12.73 65 27712 128475 29796226
Product measured potency issue 14.84 12.73 5 27772 99 29924602
Cellulitis 14.74 12.73 13 27764 46771 29877930
Pulmonary oedema 14.71 12.73 80 27697 43895 29880806
Cerebrovascular accident 14.66 12.73 35 27742 83442 29841259
Mucosal inflammation 14.63 12.73 5 27772 30489 29894212
Urinary tract infection 14.49 12.73 29 27748 73630 29851071
Electrocardiogram P wave abnormal 14.43 12.73 5 27772 108 29924593
Coronary artery disease 14.28 12.73 15 27762 49697 29875004
Pneumothorax 14.22 12.73 40 27737 16153 29908548
Large intestine anastomosis 14.21 12.73 4 27773 42 29924659
Fluid retention 14.06 12.73 3 27774 24995 29899706
Hepatitis 13.89 12.73 49 27728 22307 29902394
Angina pectoris 13.88 12.73 5 27772 29513 29895188
Postoperative delirium 13.88 12.73 4 27773 46 29924655
Systemic inflammatory response syndrome 13.71 12.73 23 27754 6523 29918178
Myotonia 13.65 12.73 4 27773 49 29924652
Low birth weight baby 13.61 12.73 22 27755 6054 29918647
Cardiac procedure complication 13.55 12.73 6 27771 253 29924448
Airway complication of anaesthesia 13.53 12.73 5 27772 131 29924570
Orthostatic hypotension 13.24 12.73 3 27774 23976 29900725
Muscle spasms 13.21 12.73 25 27752 64813 29859888
Nervous system disorder 13.20 12.73 34 27743 13035 29911666
Glossoptosis 13.18 12.73 5 27772 141 29924560
Hyperbilirubinaemia 13.10 12.73 40 27737 16902 29907799
Heart rate decreased 13.03 12.73 46 27731 20948 29903753
Non-cardiogenic pulmonary oedema 12.86 12.73 8 27769 681 29924020
Post procedural haematoma 12.84 12.73 11 27766 1536 29923165
Hypoaesthesia 12.81 12.73 19 27758 54211 29870490
Mean arterial pressure decreased 12.77 12.73 5 27772 154 29924547
Heparin-induced thrombocytopenia 12.75 12.73 20 27757 5363 29919338
Thrombophlebitis superficial 12.74 12.73 14 27763 2655 29922046

Pharmacologic Action:

SourceCodeDescription
ATC N05CD08 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
MeSH PA D000759 Adjuvants, Anesthesia
MeSH PA D000777 Anesthetics
MeSH PA D018686 Anesthetics, Intravenous
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D006993 Hypnotics and Sedatives
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine
CHEBI has role CHEBI:35474 minor tranquilisers
CHEBI has role CHEBI:35488 cns depressants
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:35623 antiepileptic
CHEBI has role CHEBI:35717 sedatives
CHEBI has role CHEBI:38869 general anaesthetic
CHEBI has role CHEBI:51371 muscle relaxants
CHEBI has role CHEBI:68495 type i programmed cell-death inducer
CHEBI has role CHEBI:91016 gabaa receptor agonists

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Feeling agitated indication 24199005
Anxiety indication 48694002
General anesthesia indication 50697003
Sedation indication 72641008
Conscious sedation indication 314271007
Local anesthesia indication 386761002
Sedation as Adjunct to Anesthesia indication
Induce Anterograde Amnesia indication
Sedation in Intubated Patients indication
Preoperative Anxiety indication
Insomnia off-label use 193462001
Status epilepticus off-label use 230456007 DOID:1824
Cocaine-Associated Acute Ischemic Heart Disease off-label use
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Cirrhosis of liver contraindication 19943007 DOID:5082
Shock contraindication 27942005
End stage renal disease contraindication 46177005 DOID:784
Chronic heart failure contraindication 48447003
Pregnancy, function contraindication 289908002
Coma contraindication 371632003
Angle-closure glaucoma contraindication 392291006 DOID:13550
Hemodynamic instability contraindication 422773005
Peripheral Vasoconstriction contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.07 Basic
pKa2 2.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
5MG/SPRAY NULLYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NULLSAL May 21, 2022 NEW PRODUCT
EQ 50MG BASE/10ML (EQ 5MG BASE/ML) SEIZALAM MERIDIAN MEDCL TECHN N209566 Sept. 14, 2018 RX SOLUTION INTRAMUSCULAR Sept. 14, 2025 TREATMENT OF STATUS EPILEPTICUS IN ADULTS
5MG/SPRAY NULLYZILAM UCB INC N211321 May 17, 2019 RX SPRAY NULLSAL May 17, 2026 ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENTS USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.74 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.44 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-3/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.26 WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.12 WOMBAT-PK CHEMBL
GABA A receptor alpha-3/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 7.61 WOMBAT-PK CHEMBL
GABA-A receptor alpha-1/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 7.75 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 9.12 WOMBAT-PK CHEMBL
GABA A receptor alpha-5/beta-2/gamma-3 Ion channel POSITIVE ALLOSTERIC MODULATOR Ki 8.26 WOMBAT-PK CHEMBL
Multidrug resistance protein 1 Transporter Km 4.35 WOMBAT-PK
Cytochrome P450 3A4 Enzyme Km 6 WOMBAT-PK
Thyrotropin-releasing hormone receptor GPCR ANTAGONIST Ki 5.49 IUPHAR
GABA-A receptor; anion channel Ion channel Ki 8.70 CHEMBL
Translocator protein Membrane receptor Ki 8.70 CHEMBL

External reference:

IDSource
4019839 VUID
N0000147927 NUI
D00550 KEGG_DRUG
59467-96-8 SECONDARY_CAS_RN
4017813 VANDF
4019839 VANDF
C0026056 UMLSCUI
CHEBI:6932 CHEBI
08J PDB_CHEM_ID
CHEMBL1200420 ChEMBL_ID
CHEMBL655 ChEMBL_ID
D008874 MESH_DESCRIPTOR_UI
DB00683 DRUGBANK_ID
4192 PUBCHEM_CID
3342 IUPHAR_LIGAND_ID
4497 INN_ID
R60L0SM5BC UNII
203128 RXNORM
130935 MMSL
24970 MMSL
32073 MMSL
5114 MMSL
d00301 MMSL
001467 NDDF
004585 NDDF
26800000 SNOMEDCT_US
373476007 SNOMEDCT_US
84213009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-3566 SYRUP 2 mg ORAL ANDA 25 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2305 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2305 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2306 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2307 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2308 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2308 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 29 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2587 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0409-2596 INJECTION, SOLUTION 5 mg INTRAMUSCULAR ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0574-0150 SYRUP 2 mg ORAL ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6056 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6057 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6059 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6060 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6061 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6063 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6190 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6209 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6210 INJECTION 1 mg INTRAMUSCULAR ANDA 27 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 0641-6211 INJECTION 5 mg INTRAMUSCULAR ANDA 27 sections
Seizalam HUMAN PRESCRIPTION DRUG LABEL 1 11704-650 INJECTION, SOLUTION 5 mg INTRAMUSCULAR NDA 32 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 17478-523 INJECTION 1 mg INTRAVENOUS ANDA 28 sections
Midazolam HUMAN PRESCRIPTION DRUG LABEL 1 17478-524 INJECTION 5 mg INTRAVENOUS ANDA 28 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0146 SYRUP 2 mg ORAL ANDA 27 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0205 SYRUP 2 mg ORAL ANDA 25 sections
Midazolam Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-3566 SYRUP 2 mg ORAL ANDA 24 sections
Midazolam hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 23155-600 INJECTION, SOLUTION 1 mg INTRAMUSCULAR ANDA 24 sections
Midazolam hydrochloride Human Prescription Drug Label 1 23155-601 INJECTION, SOLUTION 5 mg INTRAVENOUS ANDA 24 sections
MIDAZOLAM HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-610 INJECTION, SOLUTION 1 mg INTRAVENOUS NDA 30 sections
MIDAZOLAM HYDROCHLORIDE HUMAN PRESCRIPTION DRUG LABEL 1 44567-611 INJECTION, SOLUTION 1 mg INTRAVENOUS NDA 30 sections